Table 3 Clinical presentation of the COVID-19 groups
From: The severity and atypical presentations of COVID-19 infection in pediatrics
Studied variables | COVID-19 groups | Test f sig. | P value | |
|---|---|---|---|---|
Group I N = 295 | Group II N = 103 | |||
Dry cough n (%) | 74 (25.1%) | 81 (78.6%) | 92.09 | < 0.001** |
Tachypnea n (%) | 70 (23.7%) | 96 (93.2%) | 39.39 | < 0.001** |
Rhinorrhea | 73 (24.7%) | 0 (0.0%) | 30.17 | < 0.001** |
Sore throat n (%) | 73 (24.7%) | 0 (0.0%) | 31.21 | < 0.001** |
Headache n (%) | 165 (55.9%) | 75 (72.8%) | 9.09 | 0.003* |
Fatigue n (%) | 177 (60.0%) | 53 (51.5%) | 2.58 | 0.13 |
Vomiting or diarrhea n (%) | 127 (43.1%) | 11 (10.7%) | 35.32 | < 0.001** |
Fever n (%) | 274 (92.9%) | 103 (100%) | 7.74 | 0.005* |
Shock n (%) | 17 (5.7%) | 70 (68.0%) | 57.43 | < 0.001** |
Hypoxia n (%) | 33 (11.2%) | 103 (100%) | 267.7 | < 0.001** |
Acute pancreatitis manifestations | 0 (0.0%) | 5 (4.8%) | 14.5 | < 0.001** |
Deep venous thrombosis manifestations | 5 (1.7%) | 0 (0.0%) | 1.77 | 0.18 |
Kawasaki like diseases | 0 (0.0%) | 4 (3.9%) | 11.77 | 0.001** |
Fever duration after admission, days | ||||
 Mean ± SD | 7.39 ± 3.97 | 9.76 ± 4.25 | U |  |
 Median (Range) | 7 (2–16) | 6 (6–20) | 1.39 | 0.16 |